Immunome, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Immunome, Inc. (IMNM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $17.31 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-11
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $17.79, a 129.25% increase year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $7.76, a 46.92% decline year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $14.62, a 249.76% increase year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $4.18, a 44.41% decline year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $7.67, a 29.37% decline from fiscal 2024.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $10.86, a 78.33% increase from fiscal 2023.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $6.09, a 129.81% increase from fiscal 2022.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.65, a 83.93% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.31 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $17.79 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $7.67 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $7.53 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $6.35 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | $7.76 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | $10.86 10-K · filed 2026-03-03 | |||
| 2024-09-30 | $11.47 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $13.49 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $14.62 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $6.09 10-K · filed 2025-03-19 | |||
| 2023-09-30 | $3.67 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $3.67 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | $4.18 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $2.65 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $2.65 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $2.65 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | $7.52 10-Q · filed 2023-05-05 | |||
| 2021-12-31 | $16.49 10-K · filed 2023-03-16 | |||
| 2021-09-30 | $17.77 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |